By: Ross Keller, 4th year PhD candidate in the Biomedical Sciences Graduate Program
Cancer cells. Image credit: National Cancer Institute (Wikimedia Commons)
In this fifth and final post of the War on Cancer series, I will discuss the future of cancer treatment. I will also tie in my previous posts of the series, which include:
- How Can We Win the War on Cancer?
- Targeted Therapy
- Tumor Relapse
- Tumors as Ecological Systems
As I mentioned in Part 1, cancer is not one disease, but thousands, and these thousands of different diseases evolve as time goes on. Current treatments have improved greatly over the years, meaning people with cancer are living longer than ever before. New ways of treating cancer, however, will be needed to ultimately cure it.
Current research suggests that there will likely be three stages to the future of treatment: (1) discovering more vulnerabilities to target, (2) quickly mapping the genetic profile of individual tumors, and (3) developing drugs that will not only combat a tumor, but keep it from relapsing.
By: Ross Keller, 3rd year PhD candidate in the Biomedical Sciences Graduate Program
In an earlier post, I outlined a potential roadmap for the War on Cancer. I stated that in order to win, we need to define the genetic components of a specific cancer and design treatments based on that component. This is called targeted therapy, and it has actually already been used with success in some cancers, including certain types of leukemia, lung cancer, breast cancer, and melanoma. But what makes a good targeted therapy?
The hallmarks of a good targeted therapy are: specificity, potency, and ability to keep a cancer from relapsing. The best targeted therapies will kill cancer cells only and will do it efficiently so a resistant tumor does not occur following treatment.